CAMBRIDGE, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. today announced that it will present a poster at the 2015 San Antonio Breast Cancer Symposium, taking place December 8-12, 2015, at the Henry B. Gonzalez Convention Center in San Antonio, TX.
The poster details are as follows:
Title: XMT-1522 Induces Tumor Regressions in Pre-Clinical Models Representing HER2-Positive and HER2 Low-Expressing Breast Cancer
Abstract Number: P4-14-28
Poster Session: Poster Session 4, HER2-Targeted Therapy
Date: Friday, December 11, 2015
Time: 7:30 a.m. – 9:00 a.m. CST
Presenter: Donald A. Bergstrom, M.D., Ph.D., Chief Medical Officer, Mersana Therapeutics
XMT-1522, Mersana's lead product candidate, is a novel HER2-targeting therapy based on Mersana's Fleximer® immunoconjugate technology that carries an average of 15 proprietary auristatin payload molecules.
The annual Symposium provides a forum for sharing new breast cancer insights and data. The meeting is sponsored by the Cancer Therapy & Research Center at UT Health Science Center San Antonio, the American Association for Cancer Research and Baylor College of Medicine. For more information, visit http://www.sabcs.org/.
About Mersana Therapeutics
Mersana Therapeutics is advancing a proprietary pipeline of targeted oncology therapeutics leveraging its game-changing Fleximer® immunoconjugate technology. Mersana's first product candidate XMT-1522 has the potential to address significant unmet needs and improve patient outcomes in multiple oncology indications. Fleximer-based immunoconjugate molecules have been shown to have superior efficacy, including with targets previously considered not amenable to antibody-drug conjugate approaches. Mersana has collaborations utilizing Fleximer technology with Takeda, Merck KGaA, and Asana BioSciences. For more information, please visit www.mersana.com.
Source:Mersana Therapeutics, Inc.